James R. Whittle

A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation

Zuoren Yu, Chenguang Wang, Min Wang et al. · The Journal of Cell Biology · 2008 · 364 citations · Full text

Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer

Delphine Mérino, James R. Whittle, François Vaillant et al. · Science Translational Medicine · 2017 · 190 citations

Breast Oncology, Bh3 Mimetics, Medicine +13

Modeling Breast Cancer Using CRISPR-Cas9–Mediated Engineering of Human Breast Organoids

Johanna F. Dekkers, James R. Whittle, François Vaillant et al. · JNCI Journal of the National Cancer Institute · 2019 · 177 citations · Full text

Breast Oncology, Engineering, Functional Heterogeneity +18

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

Sheau Wen Lok, James R. Whittle, François Vaillant et al. · Cancer Discovery · 2019 · 143 citations · Full text

First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma

James R. Whittle, Jason D. Lickliter, Hui Gan et al. · Journal of Clinical Neuroscience · 2015 · 112 citations

Nanomedicine, Neuro-oncology, Drug Targeting +11